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1. INTRODUCTION
jj
jj
Despite the continuous improvement of CF care, respiratory care remains the main cause 
of morbidity and mortality.
Oxygen therapy is the standard of care for CF patients with hypoxemia. To timely identify 
patients who may need short-term or long-term oxygen therapy (LTOT):
sj SatO2 should be evaluated at every visit.
sj SatO2 should be evaluated during standardized exercise (e.g. 6 min walk test) routinely. 
sj Nocturnal capnography and/or oximetry are recommended in symptomatic patients 
(e.g. abnormal saturation at rest, decreased sleep quality, frequent awakenings or mor-
ning headaches). During exacerbations, oximetry may help adapt short-term oxygen 
therapy (see also Chapter “Clinical Evaluation”).
jj Non-invasive ventilation (NIV) in CF is most commonly used during acute respiratory fai-
lure, chronic hypercapnic respiratory failure or exercise. The use of NIV in this context has 
increased exponentially over the past 2 decades. 
js The main physiological effects of NIV are depicted in Figure 1. 
js In addition, NIV is associated with less traumatic and infectious complications com-
pared to invasive ventilation. NIV allows the patient to eat, move and communicate. This 
improves patient comfort and prevents the use of sedation. 
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Figure 1: Main physiological effects of NIV
Unloading of the respiratory muscles
Decreased work of breathing
Improved alveolar ventilation
Improved gas exchange
Improved respiratory muscle performance 
Improved exercise tolerance
Decreased dyspnea
2. OXYGEN THERAPY
2.1 Indications for oxygen therapy in CF
jj So far, there are no standard criteria to guide prescription of oxygen in CF but clas-
sic recommendations used for chronic obstructive pulmonary disease provide guidance. 
Therefore, oxygen therapy in CF should be considered in the following situations :
js PaO2<7.3 kPa (55 mmHg) or SatO2 ≤ 88% at rest
js PaO2<7.9 kPa (59 mmHg) or SatO2 ≤ 89% at rest with evidence of cor pulmonale
4.11 Oxygen therapy and non invasive ventilation.indd   1 30/05/18   11:54 PM
2 4.11 OXYGEN THERAPY AND NON-INVASIVE VENTILATION (NIV)
js PaO2 < 7.3kPa (55 mmHg) or SatO2 ≤ 88% during exercise if oxygen therapy improves 
exercise capacity
js Desaturation during sleep (<88%) with signs or symptoms of nocturnal hypoxemia 
(e.g. impaired cognitive function, morning headaches, restlessness, or insomnia)
jj In CF, oxygen therapy is usually prescribed in the following situations:
js During respiratory exacerbations associated with hypoxemia to allow a SatO2 
between 90 and 92% (for hypercapnic patients a lower SatO2 target of 89-90% may be 
considered if not treated with NIV).
js During chronic respiratory failure: LTOT is the standard of care for hypoxemic CF 
patients to allow a SatO2 between 90 and 92% (for hypercapnic patients NIV should also 
be considered).
js During physiotherapy or exercise: patients with normal SatO2 at rest but desatura-
tion during exercise are eligible for ambulatory oxygen therapy if exercise capacity is 
improved with oxygen. Oxygen should be titrated to limit exercise desaturation (target 
SatO2 > 90%).
js For nocturnal desaturation: 
 – For patients who desaturate during sleep, evaluation with a sleep study (to assess for
sleep-disordered breathing) should be considered.
 – Nocturnal hypoventilation typically precedes daytime hypoventilation. It is considered
to be due to a significant fall in tidal volume which is more pronounced during REM
sleep. Table 1 presents potential causes of hypoventilation in CF.
 – No standard criteria are currently available to define the cut-off level of nocturnal
hypoxemia which is clinically significant and merits nocturnal oxygen initiation. In ge-
neral terms,
 • a SatO2 < 90% for ≥ 10% of the total sleep or
 • a SatO2 drop of ≥ 4% below baseline for ≥ 5 min are considered significant.
 – In case of nocturnal hypoventilation, concomitant hypercapnia must be assessed
and treated if necessary (see below).
js At altitude/air travelling: CF patients may become hypoxemic at altitude but are 
usually asymptomatic. Resting sea-level SatO2 is not reliable to predict hypoxemia at al-
titude. For patients whose eligibility to be at altitude is in doubt, hypoxia inhalation tests 
are recommended before travelling. For more information on this subject (see Chapter 
“Travelling, altitude and diving”).
Table 1: Potential causes of hypoventilation in CF (adapted from1)
Respiratory muscle weakness due to muscle waisting and dysfunction
Poor chest wall elasticity due to kyphosis
Central nervous system depression due to opioids administered for chronic pain
Sleep disordered breathing due to decreased tidal volume
Note: Nocturnal desaturations are common during exacerbations and usually improve with treatment
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3. NIV
3.1 Indications for NIV in CF
jj So far, no standard criteria for NIV initiation are available in CF. Classic recommen-
dations used for chronic obstructive pulmonary disease or neuromuscular disorders may 
provide guidance but are not always pertinent in CF. Taking into account these limitations, 
NIV may be considered when the following criteria are met :
1. Symptoms (fatigue, dyspnea, morning headache etc.)
and
2. Physiological criteria (one of the following):
a) PaCO2 ≥ 55 mmHg.
b) PaCO2 50–54 mmHg and nocturnal desaturation (i.e. oxygen saturation measured by
pulse oximeter ≤ 88% for 5 continuous minutes while receiving oxygen therapy ≥ 2 L/min).
c) PaCO2 50–54 mmHg and hospitalization related to recurrent episodes of hypercapnic 
respiratory failure (≥ 2 episodes in a 12-month period).
2.2 Practical aspects of long-term oxygen therapy (LTOT) 
jj There are three types of oxygen delivery systems available: concentrators (stationary or 
portable), liquid oxygen (backup unit and portable liquid oxygen flask) and compressed 
gas cylinders. Concentrators or liquid oxygen are the systems used most frequently in CF. 
jj The general recommendations of oxygen prescription in Switzerland can be found in the 
site of the Swiss Association of Pulmonology (www.pneumo.ch).
jj Some considerations to guide prescription of LTOT are shown in Table 2. 
Table 2: Considerations for prescribing LTOT 
The indication and titration of oxygen therapy should be evaluated regularly
Oxygen needs should be assessed at rest, during exercise and during sleep
The choice of the equipment should be individualized to meet patients’ needs at a sustainable 
cost 
Encouraging an active lifestyle should be a central point. For that reason
– portable systems should be offered in addition to static systems
–  oxygen conserving systems, such as reservoir cannulas or on-demand oxygen pulse 
devices, should be considered to prolong oxygen supply of portable systems and 
improve mobility
Regular controls of SatO2 measurement need to be performed at rest as well as during exer-
cise because open mouth respiration during effort may affect the intake of O2 and positional 
variations may alter its efficacy.
Psychological aspects (e.g. embarrassment or depression) should be addressed
All patients using oxygen therapy should be informed on oxygen safety issues and material 
maintenance
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jj In CF NIV may be indicated in the following situations:
js During an acute severe respiratory exacerbation: in case of hypoxemia with or wi-
thout hypercapnia in severy ill patients. Because of the extremely poor outcomes of CF 
patients with invasive ventilation, NIV is preferred when possible and is used as a first 
line treatment to prevent worsening. 
js During chronic hypercapnic respiratory failure: NIV should be considered in case 
of documented significant and symptomatic nocturnal or diurnal hypercapnia. Sleep 
quality is often improved with NIV.
js During palliative care: in this context, quality of life and also control of dyspnea and 
anxiety are a priority. The goal of NIV (palliation of symptoms) should be explicit and NIV 
can be discontinued at any time if the burden of treatment outweights the benefit (see 
also Chapter “Palliative and end-of-life care”).
js During physiotherapy: NIV has been used as an adjunct to airway clearance techniques 
in patients with moderate to severe disease (see also Chapter “Physiotherapy”).
js During exercise: NIV may be justified to decrease dyspnea, increase oxygenation 
and improve exercise tolerance in patients in whom dyspnea and fatigue limit effective 
training. 
js In pregnancy: there is limited information on the safety and efficacy of NIV in pregnant 
CF patients both in an acute and chronic setting. NIV may be considered during pregnan-
cy (to avoid intubation and to allow an acceptable length of gestation) or intrapartum. 
3.2 Contraindications for NIV in CF
jj Most contraindications are relative and have been used as exclusion criteria in clinical 
studies. 
jj Even in the presence of these contraindications (Table 3), decision of NIV should be indi-
vidualized. If invasive ventilation is not considered appropriate (e.g. in severe cases where 
transplantation is not considered), NIV may be attempted. 
3.3 Practical aspects of NIV 
jj NIV may be initiated outside the ICU (emergency room, intermediate care, controlled ward 
environment) if caregivers are used to this technique. 
jj NIV can be used just during the night, for a part of the day or for 24h as indicated by the 
clinical status. 
jj At patient discharge with NIV, some points to consider are:
js Support system: service and maintenance 365 days a year.
js Requirement for battery backup if dependence increases (to use for transport or in case 
of power failure). 
js Requirement of a backup machine if regular NIV use approaches ≥ 16 hours per day.
js For material maintenance and cleaning refer to the specific manufacturer requirements.
3.4 Ventilators, interfaces and humidification
jj NIV can be delivered using either a pressure or a volume preset ventilator. The setting of 
the ventilator seems to be more important than the ventilator mode. 
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jj Ventilatory modes: Pressure targeted modes are preferred (better leak compensation, avoi-
dance of high peak pressures). Among pressure targeted modes, bi-level positive airway 
pressure (Bi-PAP) is used by the majority of patients mainly because of better comfort. 
jj Ventilatory settings: the ventilator settings are adjusted to relieve symptoms associated 
with alveolar hypoventilation. They are adapted according to the SpO2, blood gases, tidal 
volume and respiratory rate. 
js EPAP: in cases of Bi-PAP with expiratory ports, a minimum level of 4 cmH2O is recom-
mended to prevent CO2 rebreathing. Various benefits are associated with EPAP: stabili-
zation of the upper airway during sleep, recruitment of the alveoli as well as increase in 
functional residual capacity, decreased atelectasis and reduction of the inspiratory work 
required to trigger inspiration in patients with intrinsic PEEP. 
js IPAP: is titrated to achieve sufficient volume ventilation and normalization of PaCO2. 
js Cycling criteria: expiratory cycling is titrated above 35% of inspiratory peak flow to 
improve patient-ventilator synchrony and to reduce dynamic hyperinflation.
jj Interfaces: many different interface types are currently available and each is associated 
with different advantages and disadvantages (Table 4). Nasal masks are the most appro-
priate for CF patients allowing to cough and expectorate, but also for being less associated 
with gastric distension. Nasal obstruction or mouth leaks may limit their use and full face-
masks are then preferred.
jj Humidification: NIV can lead to excess loss of water vapor → oral/nasal dryness → more 
copious secretions. To alleviate these effects, adequate fluid intake and heated humidifi-
cation are required. 
Table 3: Contraindications of NIV (adapted from2)
Absolute Uncontrolled hemodynamic instability
Life threatening hypoxemia (except if rapidly controlled by NIV)
Impossibility to protect the airways
• Coma, confusion or agitation (except if they occur due to hypercapnia)
• Risk of bronchoaspiration (e.g. vomiting)
Mechanical problems
• Cranio-facial trauma or burn
• Recent facial, upper airway or gastro-oesophageal  surgery
• Upper airway obstruction
Gastrointestinal bleeding
Undrained pneumothorax
Relative Hypercapnic coma
Controlled hemodynamic instability 
Abundant secretions 
Anxiety
4.10 Oxygen therapy and non invasive ventilation.indd   5 30/05/18   11:54 PM
6 4.11 OXYGEN THERAPY AND NON-INVASIVE VENTILATION (NIV)
3.5 Nutrition during NIV 
jj Excessive dyspnea and NIV dependency make eating difficult. Adequate fluid and nutrient 
intake to meet patients’ nutritional requirements is important. 
jj If long term NIV is expected, Percutaneous Endoscopic Gastrostomy (PEG) feeding should 
be considered.
jj When nasogastric tubes are used they can cause problems with mask fitting and air leaks. 
Small bore tubes are preferable in this situation.
jj Simple measures may improve tolerance and decrease the risk of bronchoaspiration:
js When possible, smaller, more regular meals are recommended rather than large meals. 
js During enteral feeding, patients should not be in a supine but rather in a semi-sitting 
position. 
3.6 Administration of inhaled drugs during NIV
jj Data on aerosol delivery during NIV are very limited.
jj Whenever possible nebulized drugs should be administered off NIV.
jj In NIV-depended patients, inhaled drugs can be administered
js By using a metered dose inhaler and a spacer: the drug is administered into the venti-
lator circuit or 
js By adding a nebulizer to the circuit: a T-piece is placed, preferably between the exhala-
tion valve and the patient (to decrease loss of drug in the circuit although this increases 
dead space ventilation).
Table 4:  Commonly used types of interfaces, advantages and disadvantages 
(adapted from2)
Interface Advantages Disadvantages
Nasal mask Good for long-term use Problems with mouth leaks or nasal 
pathology
Oronasal mask Can solve problems with 
mouth leaks
Can be claustrophobic
Theoretical risk of aspiration after 
vomiting
Nasal plugs No pressure over nasal bridge
Useful for claustrophobic patients
Can be used by patients wearing 
spectacles
Can slip off face, problems with 
mouth leaks or nasal pathology
Full-face mask Useful for claustrophobic patients 
Useful in case of nasal and facial 
pressure sores 
Short-term use in acute care settings
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Table 5:  Potential practical problems during NIV and suggested solutions 
(adapted from2)
Complications due to Associated symptom/sign Potential solutions 
Interface Discomfort
Skin erythema 
Skin pressure sores or ulcers
Repositioning, change the tightness of 
the straps, change the size and/or type 
of the interface
Use of a skin protection dressing
Consider allergy to mask material or 
cleaning product
Claustrophobia Discussion of specific concerns and 
reassurance, relaxation techniques, 
anxiolysis
Difficulty wearing spectacles Some masks have straps to allow 
wearing glasses
Air flow Air leaks Repositioning, change the tightness of 
the straps, change the size and/or type 
of the interface.
Be sure that the straps or cushioned 
parts of the mask are not worn
Oral or nasal dryness Use a humidifier
Adequate fluid intake to avoid 
dehydration
Nasal congestion Nasal decongestant
Gastric distension Lowering inspiratory pressure, use of 
nasal mask
Corneal irritation Measures to decrease air leaks
Eye lubricants
3.7 Troubleshooting during NIV (Table 5)
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